// App-Quantinova.ai

438 : Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

Researchers

Presenter

  • Yohann Loriot

Principal Investigators

  • Thomas Powles

  • Miguel ngel Climent Durn

  • Srikala S. Sridhar

  • Joaquim Bellmunt

  • Daniel Peter Petrylak

  • Jing Wang

  • Nuno Matos Costa

  • Robert J Laliberte

  • Alessandra Di Pietro

  • Petros Grivas

  • Cora N. Sternberg

Medical Centers

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Department of Surgery, Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

  • Yale Cancer Center, New Haven, CT

  • Pfizer Inc., Cambridge, MA

  • Pfizer, Porto Salvo, Portugal

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, Milan, Italy

  • Department of Medicine, Division of Medical Oncology, University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, WA

  • Weill Cornell Medicine, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, New York, NY

Locations

  • France

  • United Kingdom

  • Spain

  • Canada

  • United States

  • Portugal

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A